Mesa Laboratories Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the annual meeting of shareholders held by Mesa Laboratories, Inc. on August 22, 2025. The company is incorporated in Colorado and its common stock trades on The Nasdaq Stock Market under the symbol MLAB.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder voting results. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. Investors should refer to the company's most recent Form 10-K or 10-Q for financial metrics.
Material Changes and Voting Results
Of the 5,501,454 shares entitled to vote, 5,203,377 shares were represented at the meeting. The following matters were approved:
- Proposal 1 (Election of Directors): All seven nominees were elected to one-year terms. The highest "For" vote was received by Mark C. Capone (4,845,315), and the lowest by John J. Sullivan (4,690,793). Broker non-votes totaled 316,877 for all director nominees.
- Proposal 2 (Ratification of Auditors): Shareholders approved the selection of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2026. The vote was 5,200,789 For, 1,732 Against, and 856 Abstain.
- Proposal 3 (Executive Compensation): The compensation of named executive officers was approved on a non-binding advisory basis with 4,476,544 votes For, 275,297 Against, and 134,659 Abstain.
- Proposal 4 (Equity Plan Amendment): An amendment to the 2021 Equity Incentive Plan was approved with 4,601,685 votes For, 247,476 Against, and 37,339 Abstain.
Board Committee Appointments
Following the election, the Board appointed the following committee members:
- Audit Committee: R. Tony Tripeny (Chair), Jennifer S. Alltoft, Mark C. Capone.
- Compensation Committee: Mark C. Capone (Chair), Shannon M. Hall, R. Tony Tripeny.
- Nominating and Corporate Governance Committee: Jennifer S. Alltoft (Chair), Shannon M. Hall, Shiraz S. Ladiwala.
Outlook, Risks, and Contingencies
This filing does not provide management commentary on future outlook, specific risks, or contingencies beyond the standard disclosure that the voting results are more fully described in the proxy statement.
Key Facts for Investor Verification
- Verify the full text of the 2021 Equity Incentive Plan amendment approved in Proposal 4 to understand changes to share availability or grant terms.
- Review the proxy statement referenced in the filing for detailed executive compensation data and director biographies.
- Confirm the audit engagement with Baker Tilly US, LLP for the fiscal year ending March 31, 2026.
- Note that 316,877 broker non-votes occurred for director elections and the equity plan amendment, which may impact future voting thresholds if quorum requirements change.